Chengdu Tianfu International Bio-Town Investment & Development

What Chengdu Tianfu International Bio-Town Investment & Development does

Chengdu Tianfu International Bio-Town Investment & Development Group (成都天府国际生物城发展集团有限公司) is a state-owned enterprise established on May 10, 2016, jointly funded by the Chengdu High-Tech Zone Management Committee and Shuangliu District Government with 50 billion yuan in registered capital. The group develops and operates the Tianfu International Bio-Town, a 44-square-kilometer bio-pharmaceutical industrial cluster in Shuangliu District, Chengdu, structured under a "1+4+N" organizational model with four business platforms: Park Construction (via Chengdu Bio-Town Construction Co., Ltd.), Science and Technology Services (via Chengdu Guosheng Innovation Technology Service Co., Ltd.), Financial Services (via Chengdu Bio-Town Equity Investment Co., Ltd. and its fund management subsidiary), and Urban Operations (via Chengdu Bio-Town City Operations Management Co., Ltd.). As of 2025 the group has completed approximately 21 billion yuan in fixed asset investment, with total assets exceeding 300 billion yuan, an AA+ corporate credit rating, and recognition as a National Bio-industry Base and National Innovation Demonstration Park.

The group operates a four-chain-one-system functional platform that integrates innovation, supply, service, and funding chains to provide end-to-end lifecycle support for biotech tenants. Core technical and operational assets include the Bio-Link incubator system (40+ university and research projects hosted, 600+ million yuan in cumulative tenant financing), a joint innovation laboratory with Thermo Fisher Scientific, a JV with China Merchants Property Management (招商积余) for property services covering 300万㎡, a portfolio of 17 sub-funds managing over 170 billion yuan in AUM, and downstream distribution via the Smart Pharmacy O2O platform and DTP pharmacy subsidiary Sichuan Maidekai. The tenant base includes nearly 200 companies such as HitGen, Sartorius, CNBG Tianlu Rongsheng, Aurimune, Maktech Bio, Nangert, and Geshi, with select tenants achieving significant milestones in 2026 including Maktech Bio's IPO and CNBG's first domestic subcutaneous immunoglobulin approval.

Revenue is generated through five parallel streams: park development and lease of laboratory/office space (subscription/recurring), industrial development and enterprise services (professional services), returns and management fees from the 17 sub-fund financial services platform (managed services), commercial real estate operations through the China Merchants JV and wholly-owned property subsidiaries (managed services), and downstream drug distribution via the Smart Pharmacy and DTP pharmacy subsidiaries. Pricing is quote-based and not publicly disclosed. Go-to-market is direct enterprise field sales anchored on the physical bio-town park, supplemented by government promotion channels, industry conferences, WeChat official account digital media, and a Shanghai outreach office for investment promotion. The group reports total assets exceeding 300 billion yuan but does not publicly disclose specific revenue figures.

Name

Chengdu Tianfu International Bio-Town Investment & Development

Legal name

成都天府国际生物城发展集团有限公司

Website

https://cdbtgroup.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Short description

State-owned industrial park developer operating Chengdu's 44-square-kilometer Tianfu International Bio-Town bio-pharmaceutical cluster. Provides park construction, technology services, investment fund management (170+ billion yuan AUM across 17 sub-funds), and urban operations to nearly 200 biotech tenants including HitGen, Sartorius, and CNBG.

Ownership category

akta.pro rank

Product category

Bio-Industrial Park Development & Operations

NAICS

Land Subdivision (2372), Utility System Construction (2371)

SIC

Investors, Nec (6799), Land Subdividers & Developers (No Cemeteries) (6552)

akta.pro primary industry

Economic Development & Business Licensing (Local) (BPAIACAN)

akta.pro secondary industry

Development Finance & Blended Finance Facilities (BPADAOAD)

Keywords

• Bio-industrial park development
• Biotech incubation services
• Life sciences investment
• Urban operations management
• Technology services platform

Headquarters

HQ city

Chengdu

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Infrastructure, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Park Development and Management: Revenue generated from developing, operating, and managing the Tianfu International Bio-Town industrial park, including lease of laboratory and office spaces, infrastructure services, and amenity management for tenant companies.
2. Industrial Development Services: Services including investment attraction, project coordination, and enterprise services provided to biotech companies and institutions within the park ecosystem.
3. Financial Services and Investment: Returns from managing and investing in a portfolio of 17 sub-funds with over 170 billion yuan in managed assets, including capital gains, management fees, and equity returns from portfolio companies.
4. Commercial Real Estate Operations: Subsidiary operations through joint ventures such as 成都国生积余不动产管理有限公司 providing real estate management services within the bio-town.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Chengdu Tianfu International Bio-Town Investment & Development is a state-owned platform company that develops and operates the 44-square-kilometer Chengdu Tianfu International Bio-Town. It delivers four core business lines: (1) Park Construction — real estate and infrastructure development; (2) Science and Technology Services — full-lifecycle biotech enterprise support including the Bio-Link incubator; (3) Financial Services — equity, debt, and fund-of-funds investment through 17 sub-funds exceeding 170 billion yuan; and (4) Urban Operations — city management, energy, and asset operations within the park.

Product overview

Chengdu Tianfu International Bio-Town Investment & Development operates as a multi-service bio-industrial park platform with four core business segments: (1) Park Construction - real estate development and construction services; (2) Science and Technology Services - comprehensive tech services for biotech companies including incubation and property management; (3) Financial Services - investment and capital services for biotech enterprises; and (4) Urban Operations - city management and facility operations. The company manages five subsidiary platforms under a '1+5+N' organizational structure, serving over 200 biotech companies including global names like 赛多利斯 (Sartorius) and 先导 (Hitrans).

Differentiator

Problem solved

Functional benefit

Brands

• Bio-Service科技服务中心: A comprehensive service center providing shared meeting rooms, red book corner, government affairs services, and convenience services for park tenants
• Bio-Link孵化器
• 成都生物城凯悦嘉轩酒店 (Chengdu Bio-Town Hyatt Place Hotel)
• 永安湖城市森林公园
• 生物城e企学

Products and services

• Park Construction (园区建设) Real estate development and construction services for the Chengdu Tianfu International Bio-Town, covering public facility construction, industrial building development, commercial real estate, and residential property development for biotech enterprises and the surrounding community.
• Science and Technology Services (科技服务) Comprehensive full-lifecycle technology and operational services for biotech companies, including the Bio-Link incubator, shared equipment access, supply chain services, the four-chain-one-system functional platform, property management exceeding 3 million square meters, and DTP pharmacy distribution of innovative drugs.
• Financial Services (金融服务) Investment and financial services for biotech and pharmaceutical innovation enterprises, including equity investment, debt investment, and comprehensive financial services through 17 sub-funds with cumulative scale exceeding 170 billion yuan.
• Urban Operations (城市运营) City management and operations services across the 44-square-kilometer bio-town, including refined city management, energy investment management, asset operations, hotel management (including the Hyatt Place hotel), and water environment management for park tenants and residents.

Quantifiable outcome

• Nearly 200 global biotech companies attracted to the bio-town park
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core.

• Zhaoshang Jiyu (招商积余)coreStrategic or Co-development PartnerChengdu Bio-Town Group established a joint venture subsidiary — 成都国生积余不动产管理有限公司 — with Zhaoshang Jiyu (招商积余), a leading property management company, to provide professional real estate and facility management services within the bio-town park.
• Thermo Fisher Scientific (赛默飞世尔科技)coreTechnology or IntegrationEstablished a joint innovation laboratory with Thermo Fisher Scientific, providing tenant companies with access to Thermo Fisher's advanced analytical instruments, testing equipment, and technical support services within the bio-town.
• CNBG Tianlu Rongsheng (国药天坛蓉生)coreStrategic or Co-development PartnerChina National Biologics Group's blood product subsidiary, operating within the Tianfu International Bio-Town ecosystem as a major biopharmaceutical tenant and collaborative partner.
• Aurimune Biologics (欧林生物)coreStrategic or Co-development PartnerA listed innovative vaccine company operating within the bio-town, engaged in R&D and manufacturing of novel vaccines with active participation in the park's collaborative ecosystem.
• Maktech Bio (迈科康生物)coreStrategic or Co-development PartnerAn innovative vaccine development company with operations in the bio-town, developing advanced vaccine candidates with support from the park's infrastructure and investment services.

Scale indicators6 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• China Fortune Land Development: Large Chinese industrial-town developer historically operating nationwide new-town and industrial-park projects. While broader in industry focus and currently under restructuring, it is comparable in scale and in combining park development with government partnership.
• Alexandria Real Estate Equities: US-listed life-sciences REIT that develops and operates mission-critical lab and innovation campuses for biotech tenants. Represents the global benchmark for institutional life-sciences real estate platforms; not a direct competitor but a structural and operational comparable.

Direct peers

• Shanghai Zhangjiang Hi-Tech Park Development Co. Shanghai-listed (600895.SH) state-controlled developer of the Zhangjiang Hi-Tech Park, China's most established bio-pharma cluster. Operates a near-identical model combining industrial park development, science-and-tech services, and investment activities for biotech tenants, making it the most directly comparable Chinese bio-park platform.
• Suzhou Industrial Park Development Group: State-owned developer of Suzhou Industrial Park, home to BioBAY, one of China's leading bio-pharma clusters. Comparable in scale, SOE structure, and the integrated park-plus-investment model serving biotech tenants in eastern China.
• Shanghai Lingang Economic Development (Macro Link): Shanghai state-owned industrial-park developer and operator that combines zone development, infrastructure construction, and investment functions. While broader in industry focus, it shares the SOE-driven park-plus-capital platform model.

Regional players

• Beijing E-Town International Investment & Development: Beijing state-owned developer of the Beijing Economic-Technological Development Area (BDA), which hosts a major bio-pharma cluster. Highly comparable in SOE structure and integrated development/incubation model, but serves a different geography.
• Chengdu Hi-Tech Investment Development Group: Sibling Chengdu SOE under the same Chengdu High-Tech Zone Management Committee. Operates the broader Hi-Tech Zone development mandate and overlaps with Tianfu Bio-Town on tenant attraction and government-backed investment in western China.
• Wuhan Hi-Tech Holding Group: State-owned developer of Wuhan East Lake Hi-Tech Development Zone (Optics Valley), which includes bio-pharma operations. Comparable SOE park developer with biotech cluster ambitions but serving central China.
• Shenzhen Hi-Tech Investment Development: Shenzhen state-owned developer and investor focused on high-tech and bio-pharma industrial parks in southern China. Comparable in combining park development with venture-style investment in biotech tenants.
• Tianjin TEDA Investment Holding: Tianjin state-owned platform operating the Tianjin Economic-Technological Development Area, which includes bio-pharma and life-sciences activity. Similar SOE-driven integrated park and investment platform serving northern China.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries16 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments12 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chengdu Tianfu International Bio-Town Investment & Development